Compass Therapeutics vs Palisade Bio
CMPX and PALI side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CMPX and PALI compare
Palisade Bio is the larger company, worth 1.4 times as much as Compass Therapeutics ($204M against $150M).
Compass Therapeutics scores higher on the StockData Score (7 against 6 for Palisade Bio), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CMPX | PALI |
|---|---|---|
| Size and price | ||
| Market cap | $150M | $204M |
| Share price | $0.830 | $1.17 |
| Change, 1 year | −80.6% | −33.9% |
| Change, 5 years | −76.1% | −99.9% |
| Beta (5Y) | 1.27 | 0.97 |
| Employees | 39 | 100K |
| StockData Score | ||
| Total score | 7 (better) | 6 |
| Valuation score | 1 | 1 |
| Growth score | 0 | 0 |
| Performance score | 1 (better) | 0 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 408× |
| P/B | 1.0× (better) | 1.8× |
| FCF yield | −41.4% | – |
| Profitability | ||
| Operating margin | – | −9625% |
| Net margin | – | −8739% |
| Return on equity | −49.0% (better) | −75.6% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Interest coverage | – | −16042.3× |
| Current ratio | 6.79 | 20.16 (better) |
| Altman Z-score | −2.02 | 19.83 (better) |
| Piotroski F-score | 3 | 4 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | −64.6% |
| Shareholder yield | 0.00% (better) | −64.6% |
| Ownership | ||
| Held by institutions | 92.0% | 99.5% |
| Held by insiders | 26.3% | 4.7% |
| Insider net buying, 12 months | $96.8K (better) | −$124K |
| Short interest, % of float | 30.7% | 17.6% |
Go deeper
- CMPX stock overview
- CMPX income statement
- CMPX valuation and score
- PALI stock overview
- PALI income statement
- PALI valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.